VolitionRX (VNRX) Stock Price, News & Analysis

Company Overview

VolitionRx Limited, a multi-national epigenetics company, engages in the development of blood tests to help diagnose and monitor a range of cancers, and sepsis and COVID-19 in the United States and internationally. The company offers Nu.Q Vet, a cancer screening test for dogs and other animals; Nu.Q Nets for monitoring the immune system; Nu.Q Cancer for monitoring disease progression, response to treatment and minimal residual disease; Capture-PCR, an isolating and capturing circulating tumor derived DNA from plasma samples for early cancer detection; and Nu.Q Discover, a solution to profiling nucleosomes. VolitionRx Limited is based in Henderson, Nevada.

Key Stats

• Today's Range: $0.67 to $0.70
• 50-Day Range: $0.62 to $0.92
• 52-Week Range: $0.40 to $0.94
• Volume: 181,858 shs
• Average Volume: 196,136 shs
• Market Capitalization: $75.32 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

VolitionRX Stock Analysis - MarketRank™

VolitionRX scored higher than 15% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: N/A
• Analyst Rating: N/A

Consensus Rating

There is not enough analysis data for VolitionRX.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for VolitionRX are expected to grow in the coming year, from ($0.50) to ($0.33) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of VolitionRX is -2.80, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of VolitionRX is -2.80, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Short Interest

• Score: 5.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

0.20% of the float of VolitionRX has been sold short.

Short Interest Ratio / Days to Cover

VolitionRX has a short interest ratio ("days to cover") of 0.8, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in VolitionRX has recently decreased by 47.92%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

VolitionRX does not currently pay a dividend.

Dividend Growth

VolitionRX does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

0.20% of the float of VolitionRX has been sold short.

Short Interest Ratio / Days to Cover

VolitionRX has a short interest ratio ("days to cover") of 0.8, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in VolitionRX has recently decreased by 47.92%, indicating that investor sentiment is improving significantly.

News and Social Media

• Score: 0.6 / 5
• News Sentiment: N/A

Search Interest

4 people have searched for VNRX on MarketBeat in the last 30 days. This is an increase of 300% compared to the previous 30 days.

Company Ownership

• Score: 0.8 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, VolitionRX insiders have not sold or bought any company stock.

Percentage Held by Insiders

10.40% of the stock of VolitionRX is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

Only 8.09% of the stock of VolitionRX is held by institutions.

VNRX Stock Analysis - Frequently Asked Questions

How have VNRX shares performed this year?

VolitionRX's stock was trading at $0.58 on January 1st, 2025. Since then, VNRX shares have increased by 20.7% and is now trading at $0.6999.

How were VolitionRX's earnings last quarter?

VolitionRX Limited (NYSEAMERICAN:VNRX) posted its earnings results on Wednesday, November, 10th. The medical research company reported ($0.13) earnings per share for the quarter, missing the consensus estimate of ($0.11) by $0.02. The medical research company earned $0.03 million during the quarter, compared to analysts' expectations of $0.03 million.

How do I buy shares of VolitionRX?

Shares of VNRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of VolitionRX own?

Based on aggregate information from My MarketBeat watchlists, some other companies that VolitionRX investors own include Chesapeake Energy (CHKAQ), Bausch Health Cos (BHC), Avino Silver & Gold Mines (ASM), Exelixis (EXEL), T2 Biosystems (TTOO), Gilead Sciences (GILD) and Vertex Pharmaceuticals (VRTX).

Company Calendar

• Last Earnings: 11/10/2021
• Today: 8/25/2025
• Next Earnings (Estimated): 11/13/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NYSEAMERICAN
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NYSEAMERICAN:VNRX
• Previous Symbol: NYSEMKT:VNRX
• CIK: 93314
• Web: www.volitionrx.com
• Phone: (646) 650-1351
• Fax: 65 32 8172 5651
• Employees: 80
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): ($0.56)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$26.97 million
• Net Margins: -1,766.89%
• Pretax Margin: -1,781.59%
• Return on Equity: N/A
• Return on Assets: -234.05%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 0.35
• Quick Ratio: 0.35

Sales & Book Value

• Annual Sales: $1.23 million
• Price / Sales: 61.24
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: ($0.28) per share
• Price / Book: -2.50

Miscellaneous

• Outstanding Shares: 107,600,000
• Free Float: 96,405,000
• Market Cap: $75.32 million
• Optionable: Not Optionable
• Beta: 1.26